Frontage, a contract research and manufacturing organization based in Exton, PA, was picked by biotech AtheroNova to develop clinical trial supplies in preparation for a Phase I trial for a drug they hope can prevent and treat atherosclerosis, or the hardening of the arteries. Under the agreement the two entities brokered, Frontage will take care of the formulation, compounding and tabletization of AtheroNova's drug. Last month, AtheroNova celebrated a milestone when it shipped the AHRO-001 API overseas to Russia where CardioNova has begun Phase I clinical trials. While any sort of commercial approval is years away from fruition, AtheroNova is certainly optimistic that AHRO-001 and Frontage can deliver on their promises. Release